{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T19:50:32Z","timestamp":1761767432292,"version":"3.37.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Hochschule Brandenburg CAMPUS GmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>\n              <jats:italic>Mycobacterium tuberculosis<\/jats:italic> (MT) infections represent a global health problem and latent tuberculosis infection (LTBI) affects an estimated 25% of the world population. 10.6\u00a0million people fell ill with tuberculosis (TB) worldwide in 2021 and a total of 1.6\u00a0million TB-associated deaths were reported. Thus, reliable diagnosis of LTBI is crucial to ensure adequate treatment. We tested three novel MT antigens of the dormancy survival regulator (DosR) complex, ACR, Rv1733, Rv2626, for improvement of MT specific interferon gamma release assays (IGRA) for diagnosing TB. Furthermore, we specifically investigated the potential of the complement factor C5a and the toll like receptor (TLR) agonists CpG ODN as well as Poly(I: C) as costimulators in order to increase diagnostic quality of MT IGRAs. Three MT IGRAs were evaluated, i.e. our in-house IGRA, a prototypic EUROIMMUN Quan-T-Cell TB assay and the gold standard QuantiFERON Tb-Gold Plus assay.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>\n              <jats:italic>In this single-center<\/jats:italic>,<jats:italic> prospective trial<\/jats:italic>, whole blood from 71 patients with tuberculosis disease was stimulated using our in-house IGRA with ACR, Rv1733, Rv2626 compared to the current gold standard MT antigen formulation encompassing MT antigens ESAT-6, CFP-10 and TB10.4. Further, C5a, CpG ODN and Poly(I: C) were tested as co-stimulators. IFN-\u03b3 levels in plasma were quantified using ELISA.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The three novel antigens ACR, Rv1733 and Rv2626 failed to elicit equal or stronger IFN-\u03b3-responses compared to the gold standard antigen formulation with ESAT-6, CFP-10 and TB10.4. The TLR9 agonist CpG ODN increased IFN-\u03b3 responses in whole blood of tuberculosis patients using our in-house assays (6,768\u2009\u00b1\u200921,097 mlU\/ml vs. 2,971\u2009\u00b1\u20094,780 mlU\/ml, <jats:italic>p<\/jats:italic>\u2009=\u20090.31), yet not significantly. The same trend was found for the prototypic EUROIMMUN Quan-T-Cell TB assay (3,355\u2009\u00b1\u20095,425 mlU\/ml vs. 2,548\u2009\u00b1\u20094,145 mlU\/ml, <jats:italic>p<\/jats:italic>\u2009=\u20090.1) and the QuantiFERON Tb-Gold Plus assay (3,627\u2009\u00b1\u20095,992 mlU\/ml vs. 2,635\u00a0m\u2009\u00b1\u20094,475 mlU\/ml, <jats:italic>p<\/jats:italic>\u2009=\u20090.08, for tube 1; 3,257\u2009\u00b1\u20095,349 vs. 2,759\u2009\u00b1\u20094,446 mIU\/ml, <jats:italic>p<\/jats:italic>\u2009=\u20090.25, for tube 2). No increase of IFN-\u03b3 release was seen using Poly(I: C) or C5a in all three assays.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>ACR, Rv1733 and Rv2626 failed to elicit equal or even better IFN-\u03b3 responses in our in-house IGRA compared to ESAT-6, CFP-10 and TB10.4 in patients with MT infection. The TLR9 agonist CpG ODN might be useful as co-stimulator in MT IGRAs.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12879-025-10577-3","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T17:30:18Z","timestamp":1738949418000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Evaluation of three novel antigens and costimulatory agents for improvement of M. Tuberculosis specific interferon gamma release assays"],"prefix":"10.1186","volume":"25","author":[{"given":"Sandra","family":"Schwarzlose-Schwarck","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Reinwald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torsten","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Hentschel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Til","family":"Kiderlen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorinja","family":"Zapf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"Herbst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"L\u00fcth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Krieger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Werner","family":"Dammermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,7]]},"reference":[{"key":"10577_CR1","unstructured":"World Health O. Global tuberculosis report 2021. Geneva: World Health Organization; 2021 2021."},{"issue":"4","key":"10577_CR2","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1183\/09031936.00214014","volume":"45","author":"K Lonnroth","year":"2015","unstructured":"Lonnroth K, Migliori GB, Abubakar I, D\u2019Ambrosio L, de Vries G, Diel R, et al. Towards Tuberculosis elimination: an action framework for low-incidence countries. Eur Respir J. 2015;45(4):928\u201352.","journal-title":"Eur Respir J"},{"issue":"10","key":"10577_CR3","doi-asserted-by":"publisher","first-page":"e1002152","DOI":"10.1371\/journal.pmed.1002152","volume":"13","author":"RM Houben","year":"2016","unstructured":"Houben RM, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation using Mathematical Modelling. PLoS Med. 2016;13(10):e1002152.","journal-title":"PLoS Med"},{"issue":"sup1","key":"10577_CR4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1080\/24745332.2022.2035540","volume":"6","author":"R Long","year":"2022","unstructured":"Long R, Divangahi M, Schwartzman K. Chapter 2: transmission and pathogenesis of tuberculosis. Can J Respiratory Crit Care Sleep Med. 2022;6(sup1):22\u201332.","journal-title":"Can J Respiratory Crit Care Sleep Med"},{"issue":"6","key":"10577_CR5","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1183\/13993003.01245-2015","volume":"46","author":"H Getahun","year":"2015","unstructured":"Getahun H, Matteelli A, Abubakar I, Aziz MA, Baddeley A, Barreira D, et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J. 2015;46(6):1563\u201376.","journal-title":"Eur Respir J"},{"issue":"10","key":"10577_CR6","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/S1473-3099(18)30355-4","volume":"18","author":"I Abubakar","year":"2018","unstructured":"Abubakar I, Drobniewski F, Southern J, Sitch AJ, Jackson C, Lipman M, et al. Prognostic value of interferon-gamma release assays and tuberculin skin test in predicting the development of active tuberculosis (UK PREDICT TB): a prospective cohort study. Lancet Infect Dis. 2018;18(10):1077\u201387.","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10577_CR7","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1086\/426434","volume":"40","author":"F Tissot","year":"2005","unstructured":"Tissot F, et al. Influence of bacille Calmette-Gu\u00e9rin vaccination on size of tuberculin skin test reaction: to what size? Clin Infect Dis. 2005;40(2):211\u20137.","journal-title":"Clin Infect Dis"},{"key":"10577_CR8","doi-asserted-by":"publisher","first-page":"601737","DOI":"10.1155\/2013\/601737","volume":"2013","author":"A Trajman","year":"2013","unstructured":"Trajman A, Steffen RE, Menzies D. Interferon-Gamma release assays versus tuberculin skin testing for the diagnosis of latent tuberculosis infection: an overview of the evidence. Pulm Med. 2013;2013:601737.","journal-title":"Pulm Med"},{"issue":"1","key":"10577_CR9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S1473-3099(21)00145-6","volume":"22","author":"CS Ho","year":"2022","unstructured":"Ho CS, Feng PI, Narita M, Stout JE, Chen M, Pascopella L, et al. Comparison of three tests for latent tuberculosis infection in high-risk people in the USA: an observational cohort study. Lancet Infect Dis. 2022;22(1):85\u201396.","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"10577_CR10","first-page":"443","volume":"2","author":"JA Streeton","year":"1998","unstructured":"Streeton JA, Desem N, Jones SL. Sensitivity and specificity of a gamma interferon blood test for tuberculosis infection. Int J Tuberc Lung Dis. 1998;2(6):443\u201350.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"2","key":"10577_CR11","doi-asserted-by":"publisher","first-page":"125","DOI":"10.4103\/0377-4929.118694","volume":"56","author":"F Qian","year":"2013","unstructured":"Qian F, Wang W, Qiu Z, Shen Y, He J, Li D, et al. Evaluation of a new tuberculosis-related interferon gamma release assay for tuberculosis infection diagnosis in Huzhou, eastern China. Indian J Pathol Microbiol. 2013;56(2):125\u20138.","journal-title":"Indian J Pathol Microbiol"},{"key":"10577_CR12","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ijid.2019.12.012","volume":"91","author":"C Della Bella","year":"2020","unstructured":"Della Bella C, Spinicci M, Alnwaisri HFM, Bartalesi F, Tapinassi S, Mencarini J, et al. LIOFeron(R)TB\/LTBI: a novel and reliable test for LTBI and Tuberculosis. Int J Infect Dis. 2020;91:177\u201381.","journal-title":"Int J Infect Dis"},{"issue":"1","key":"10577_CR13","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3343\/alm.2020.40.1.33","volume":"40","author":"JJ Kim","year":"2020","unstructured":"Kim JJ, Park Y, Choi D, Kim HS. Performance evaluation of a New Automated Chemiluminescent Immunoanalyzer-based Interferon-Gamma releasing assay AdvanSure I3 in comparison with the QuantiFERON-TB gold In-Tube assay. Ann Lab Med. 2020;40(1):33\u20139.","journal-title":"Ann Lab Med"},{"issue":"1","key":"10577_CR14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S1473-3099(11)70210-9","volume":"12","author":"MX Rangaka","year":"2012","unstructured":"Rangaka MX, Wilkinson KA, Glynn JR, Ling D, Menzies D, Mwansa-Kambafwile J, et al. Predictive value of interferon-gamma release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(1):45\u201355.","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"10577_CR15","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1016\/S1473-3099(20)30276-0","volume":"20","author":"G Zhou","year":"2020","unstructured":"Zhou G, Luo Q, Luo S, Teng Z, Ji Z, Yang J, et al. Interferon-gamma release assays or tuberculin skin test for detection and management of latent tuberculosis infection: a systematic review and meta-analysis. Lancet Infect Dis. 2020;20(12):1457\u201369.","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"10577_CR16","doi-asserted-by":"publisher","first-page":"e1116","DOI":"10.1093\/cid\/ciaa1822","volume":"73","author":"CE Oh","year":"2021","unstructured":"Oh CE, Ortiz-Brizuela E, Bastos ML, Menzies D. Comparing the diagnostic performance of QuantiFERON-TB Gold Plus to other tests of latent tuberculosis infection: a systematic review and Meta-analysis. Clin Infect Dis. 2021;73(5):e1116\u201325.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10577_CR17","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1128\/IAI.01137-06","volume":"75","author":"V Roupie","year":"2007","unstructured":"Roupie V, Romano M, Zhang L, Korf H, Lin MY, Franken KL, et al. Immunogenicity of eight dormancy regulon-encoded proteins of Mycobacterium tuberculosis in DNA-vaccinated and tuberculosis-infected mice. Infect Immun. 2007;75(2):941\u20139.","journal-title":"Infect Immun"},{"issue":"1","key":"10577_CR18","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12967-018-1752-8","volume":"17","author":"K Broker","year":"2019","unstructured":"Broker K, Terzenbach R, Bentzien F, Luth S, Dammermann W. Complement factors C3a and C5a mimick a proinflammatory microenvironment and increase HBV IGRA sensitivity. J Transl Med. 2019;17(1):6.","journal-title":"J Transl Med"},{"key":"10577_CR19","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jviromet.2017.07.011","volume":"248","author":"W Dammermann","year":"2017","unstructured":"Dammermann W, Dornbrack J, Broker K, Bentzien F, Luth S. CpG oligonucleotides increase HBV-specific cytokine responses in whole blood and enhance cytokine release assay sensitivity. J Virol Methods. 2017;248:195\u2013201.","journal-title":"J Virol Methods"},{"key":"10577_CR20","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jim.2014.10.011","volume":"414","author":"W Dammermann","year":"2014","unstructured":"Dammermann W, Bochmann D, Bentzien F, Komorowski L, Steinhagen K, Ullrich S, et al. CMV specific cytokine release assay in whole blood is optimized by combining synthetic CMV peptides and toll like receptor agonists. J Immunol Methods. 2014;414:82\u201390.","journal-title":"J Immunol Methods"},{"issue":"6","key":"10577_CR21","doi-asserted-by":"publisher","first-page":"2914","DOI":"10.1128\/IAI.01990-06","volume":"75","author":"A Geluk","year":"2007","unstructured":"Geluk A, Lin MY, van Meijgaarden KE, Leyten EM, Franken KL, Ottenhoff TH, et al. T-cell recognition of the HspX protein of Mycobacterium tuberculosis correlates with latent M. Tuberculosis infection but not with M. Bovis BCG vaccination. Infect Immun. 2007;75(6):2914\u201321.","journal-title":"Infect Immun"},{"issue":"10","key":"10577_CR22","doi-asserted-by":"publisher","first-page":"5020","DOI":"10.4049\/jimmunol.1103556","volume":"188","author":"CS Arlehamn","year":"2012","unstructured":"Arlehamn CS, Sidney J, Henderson R, Greenbaum JA, James EA, Moutaftsi M, et al. Dissecting mechanisms of immunodominance to the common tuberculosis antigens ESAT-6, CFP10, Rv2031c (hspX), Rv2654c (TB7.7), and Rv1038c (EsxJ). J Immunol. 2012;188(10):5020\u201331.","journal-title":"J Immunol"},{"key":"10577_CR23","doi-asserted-by":"publisher","first-page":"517","DOI":"10.3389\/fmicb.2014.00517","volume":"5","author":"MM Serra-Vidal","year":"2014","unstructured":"Serra-Vidal MM, Latorre I, Franken KL, Diaz J, de Souza-Galvao ML, Casas I, et al. Immunogenicity of 60 novel latency-related antigens of Mycobacterium Tuberculosis. Front Microbiol. 2014;5:517.","journal-title":"Front Microbiol"},{"issue":"0","key":"10577_CR24","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/j.ebiom.2015.05.026","volume":"2","author":"D Pe\u00f1a","year":"2015","unstructured":"Pe\u00f1a D, Rovetta AI, Del Hern\u00e1ndez RE, Amiano NO, Pasquinelli V, Pellegrini JM, et al. A Mycobacterium tuberculosis Dormancy Antigen differentiates latently infected Bacillus Calmette\u2013Gu\u00e9rin-vaccinated individuals. EBioMedicine. 2015;2(0):884\u201390.","journal-title":"EBioMedicine"},{"issue":"1\u20132","key":"10577_CR25","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jim.2013.08.004","volume":"396","author":"W Dammermann","year":"2013","unstructured":"Dammermann W, Wollenberg L, Bentzien F, Lohse A, Luth S. Toll like receptor 2 agonists lipoteichoic acid and peptidoglycan are able to enhance antigen specific IFNgamma release in whole blood during recall antigen responses. J Immunol Methods. 2013;396(1\u20132):107\u201315.","journal-title":"J Immunol Methods"},{"issue":"4","key":"10577_CR26","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.4049\/jimmunol.169.4.2102","volume":"169","author":"IU Schraufstatter","year":"2002","unstructured":"Schraufstatter IU, Trieu K, Sikora L, Sriramarao P, DiScipio R. Complement c3a and c5a induce different signal transduction cascades in endothelial cells. J Immunol. 2002;169(4):2102\u201310.","journal-title":"J Immunol"},{"issue":"6292","key":"10577_CR27","doi-asserted-by":"publisher","first-page":"aad1210","DOI":"10.1126\/science.aad1210","volume":"352","author":"G Arbore","year":"2016","unstructured":"Arbore G, West EE, Spolski R, Robertson AA, Klos A, Rheinheimer C, et al. T helper 1 immunity requires complement-driven NLRP3 inflammasome activity in CD4(+) T cells. Science. 2016;352(6292):aad1210.","journal-title":"Science"},{"issue":"6","key":"10577_CR28","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.immuni.2013.10.018","volume":"39","author":"MK Liszewski","year":"2013","unstructured":"Liszewski MK, Kolev M, Le Friec G, Leung M, Bertram PG, Fara AF, et al. Intracellular complement activation sustains T cell homeostasis and mediates effector differentiation. Immunity. 2013;39(6):1143\u201357.","journal-title":"Immunity"},{"issue":"12","key":"10577_CR29","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1089\/jir.1995.15.1037","volume":"15","author":"PD Drew","year":"1995","unstructured":"Drew PD, Franzoso G, Becker KG, Bours V, Carlson LM, Siebenlist U, et al. NF kappa B and interferon regulatory factor 1 physically interact and synergistically induce major histocompatibility class I gene expression. JInterferon Cytokine Res. 1995;15(12):1037\u201345.","journal-title":"JInterferon Cytokine Res"},{"issue":"5","key":"10577_CR30","first-page":"1254","volume":"36","author":"KW Lee","year":"2006","unstructured":"Lee KW, Lee Y, Kim DS, Kwon HJ. Direct role of NF-kappaB activation in toll-like receptor-triggered HLA-DRA expression. EurJImmunol. 2006;36(5):1254\u201366.","journal-title":"EurJImmunol"},{"issue":"6857","key":"10577_CR31","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/35099560","volume":"413","author":"L Alexopoulou","year":"2001","unstructured":"Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by toll-like receptor 3. Nature. 2001;413(6857):732\u20138.","journal-title":"Nature"},{"issue":"1","key":"10577_CR32","first-page":"39","volume":"19","author":"D Kabelitz","year":"2007","unstructured":"Kabelitz D. Expression and function of toll-like receptors in T lymphocytes. CurrOpinImmunol. 2007;19(1):39\u201345.","journal-title":"CurrOpinImmunol"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-10577-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-10577-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-10577-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T17:30:25Z","timestamp":1738949425000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-10577-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,7]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["10577"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-10577-3","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,7]]},"assertion":[{"value":"23 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Our study adhered to the Declaration of Helsinki regarding research carried out on humans and\/or human data. The study was approved by the Ethics Committee of the Brandenburg Chamber of Physicians (S20(a)\/2016) as well as the Berlin Chamber of Physicians (Eth-V-ZK\/17) and all patients gave informed consent for the participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"D.Z. and V.H. are employed by EUROIMMUN, a manufacturer of diagnostic reagents and co-owner of patents related to serological assays for the diagnosis of infectious diseases and the detection of immunity as a result of vaccination. EUROIMMUN provided kits for analyses at discounted rates. The other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"188"}}